21 citations
,
February 2021 in “BMJ case reports” Anabolic steroid users may face higher risk of severe COVID-19.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.